⌕
Charles River Laboratories International · CRL · NYSE
Tenet 33 · Weak
Compare
$332.16−1.00%At closeTenet 33 · Weak
$332.16−3.36 (−1.00%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Charles River Laboratories International (CRL) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 0.9% in FY25, net margin −3.6%.
The four lines that matter · FY21–FY25
Revenue ($M)▼0.9%
4,015.4
FY21→FY25CAGR +3.2%/yr
Net income ($M)—
−144.3
one-off year: see footnoteCAGR —
Free cash flow ($M)▲3.4%
518.5
FY21→FY25CAGR −0.6%/yr
Diluted EPS—
−2.91
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−3.6%

51.4mn → 49.6mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$219.2M

steady at 5.5% of revenue (−5.9% YoY).

Returns vs FCF
70%

$360.7M returned vs $518.5M of FCF in FY25. Buybacks covered by cash flow.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)4015.4Revenue−2692.1COGS1323.3Gross profit−743.1SG&A25.2Op income−169.5Tax & other−144.3Net income

-4¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
403020100%sector median net margin ~3%FY21FY25

Over this window: gross 37.7% → 33.0%. Net margin -3.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
3,976.94,015.44,050.04,129.43,976.13,540.2▼0.9%+3.2%
Cost of revenue
2,651.32,692.12,718.22,626.92,513.42,205.5▼1.0%+5.1%
Gross profit
1,325.61,323.31,331.81,502.61,462.71,334.6▼0.6%−0.2%
Selling, general & admin
725.0743.1751.0747.9665.1619.9▼1.1%+4.6%
Total operating expenses
1,166.61,298.11,104.5885.3811.7744.8▲17.5%+14.9%
Operating incomefeeds ROC rank
159.025.2227.3617.3651.0589.9▼88.9%−54.6%
Other income, net
−259.2−124.7−134.2−36.0−28.0−109.2——
Pretax income
−100.2−99.593.1581.3623.0480.7——
Income tax
−142.842.767.8100.9130.481.9▼37.1%−15.0%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
40.2−144.322.2474.6486.2398.8——
Per share
Diluted EPSbuyback-sensitive
0.96−2.910.209.229.487.60——
Diluted shares (mn)
48.5849.5651.6351.4551.3051.42▼4.0%−0.9%
Margins
Gross margin17th pct in Healthcare
33.3%33.0%32.9%36.4%36.8%37.7%▲0.1pp−4.7pp
Operating margin
4.0%0.6%5.6%14.9%16.4%16.7%▼5.0pp−16.0pp
Net margin43rd pct in Healthcare
1.0%−3.6%0.5%11.5%12.2%11.3%▼4.1pp−14.9pp
† TTM = trailing four quarters through 2026-09-26.FY24 effective tax rate was 73% vs a 17% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was −43% vs a 17% norm for this window, likely a one-time item; see the filing.
FY08 – FY20 · 13 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 13 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-18 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Charles River Laboratories International's revenue last fiscal year?

Charles River Laboratories International reported revenue of $4,015.4M in fiscal 2025, down 0.9% from fiscal 2024.

What was Charles River Laboratories International's net income?

Charles River Laboratories International reported net income of −$144.3M in fiscal 2025, a net margin of −3.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.